Morgan Stanley Downgrades Sarepta Therapeutics (SRPT) to Equalweight

Morgan Stanley analyst Matthew Harrison downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Overweight to Equalweight with a price target of $40.00 (from $113.00).

The analyst comments "Second patient death raises concerns as use in non-ambulatory patients restricted (commercial and clinical), while enhanced immunosuppressive regimen in development could mitigate risk. While deaths seems specific to non-ambulatory patients, given near-term uncertainty we downgrade to Equal-weight."

For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.

Shares of Sarepta Therapeutics closed at $36.18 yesterday.

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Sigma Lithium resumes full operations after signing TAC agreement
• Myriad Uranium completes acquisition of Rush Rare Metals